Baxter International (BAX) Receives Price Target

Baxter International (BAX) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $60 and the lowest price target forecast is $47. The average forecast of all the analysts is $50.57 and the expected standard deviation is $4.54.

Baxter International (BAX) : Zacks Investment Research ranks Baxter International (BAX) as 2, which is a Buy recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 9 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 11 research analysts is 2.94, which indicates as a Hold.


Also, In the latest statement by the brokerage house, UBS maintains its outlook on Baxter International (NYSE:BAX). The current rating of the shares is Neutral, according to the research report released by the firm. The brokerage firm raises the price target from $48 per share to $50 per share. The rating by the firm was issued on July 28, 2016.

Baxter International (NYSE:BAX): The stock opened at $46.75 on Thursday but the bulls could not build on the opening and the stock topped out at $46.78 for the day. The stock traded down to $45.91 during the day, due to lack of any buying support eventually closed down at $46.18 with a loss of -1.18% for the day. The stock had closed at $46.73 on the previous day. The total traded volume was 4,249,317 shares.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.